102 related articles for article (PubMed ID: 22987331)
21. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
22. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
25. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
26. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
[TBL] [Abstract][Full Text] [Related]
27. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
28. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
29. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.
Carter HB; Pearson JD; Waclawiw Z; Metter EJ; Chan DW; Guess HA; Walsh PC
Urology; 1995 Apr; 45(4):591-6. PubMed ID: 7536366
[TBL] [Abstract][Full Text] [Related]
32. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
J Urol; 1999 Apr; 161(4):1199-203; discussion 1203-5. PubMed ID: 10081869
[TBL] [Abstract][Full Text] [Related]
33. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
35. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
37. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
38. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen screening and mortality from prostate cancer.
Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
[TBL] [Abstract][Full Text] [Related]
40. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
Preston MA; Batista JL; Wilson KM; Carlsson SV; Gerke T; Sjoberg DD; Dahl DM; Sesso HD; Feldman AS; Gann PH; Kibel AS; Vickers AJ; Mucci LA
J Clin Oncol; 2016 Aug; 34(23):2705-11. PubMed ID: 27298404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
